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The presence of whole horse IgG in therapeutic snake antivenom preparations of high
purity is a contamination that can cause IgE-mediated allergic reactions in patients. In this
study, the immunodominant IgE and IgG-binding epitopes in horse heavy chain IgG3 were
mapped using arrays of overlapping peptides synthesized directly onto activated cellulose
membranes. Pooled human sera from patients with and without horse antivenom allergies
were used to probe the membrane. We have demonstrated that, for both cases, individuals
produce antibodies to epitopes of sequential amino acids of horse heavy chain IgG3,
although the signal strength and speciﬁcity appear to be distinct between the two groups
of patients. A single region was found to contain the dominant allergic IgE epitope. The
critical residues involved in the binding of human IgE to the epitope were determined to
include four hydrophobic amino acids followed by polar and charged residues that formed
a coil structure. This is the ﬁrst study to describe the speciﬁc amino acid sequences
involved with the immune recognition of human IgG and IgE to horse antivenom.
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y; hhcIg, horse heavy
a; HRP, horseradish
e treatment; TBS-CT,
en 20, pH 7.0; TBS-T,
0; TMB, 3,30 ,5,50-
cal Development in
nology for Innovation
aneiro, RJ, Brazil. Fax:
q.br, dsimone@ioc.
. All rights reserved.1. Introduction
Antivenom is the primary treatment for snake enve-
noming (Theakston and Warrell, 1991; Lang et al., 2000).
These immunobiological compounds contains polyclonal
antibodies raised against the one or more venoms and can
be obtained in horses, sheep or goats. Intravenous admin-
istration of antivenom to patients with snake envenoming
prevent or reverse clinical effects by the binding of the
antibodies to circulating snake toxins, which neutralizes
their activity and promote their elimination (Warrell, 1996).
Monovalent antivenoms are raised against a single snake
species, while polyvalent antivenoms are raised against
more than one specie.
These preparations are normally composed of pepsin-
reﬁned immunoglobulin fragments (F(ab’)2) that are most
S.G. De-Simone et al. / Toxicon 78 (2014) 83–9384often prepared from the plasma or serum of horses
hyperimmunized with preparations of the particular
toxin(s) in question. The appropriate administration of an
antivenom preparation can have a profound and rapid
impact on the recovery of a victim (Gutiérrez et al., 2006;
Isbister et al., 2012). However, immediate hypersensitivity
reactions to the foreign proteins in snake antivenoms are
themost severe side effects from antivenom treatment. Life
threatening reactions can be mediated by patient IgE an-
tibodies (anaphylactic) or non-IgE mechanisms (anaphy-
lactoid) (Chippaux and Goyffon, 1998; Moran et al., 1998;
León et al., 2013). Later reactions (5–26 days after admin-
istration; serum sickness or type III hypersensitivity) are
less severe that involve the immune response of the patient
to raise IgG antibodies against the horse proteins (Dart and
McNally, 2001; LoVecchio et al., 2003; Vazquez et al., 2013).
Published worldwide rates of anaphylactic reactions to
antivenom range from 1% (Visser and Chapman, 1978;
Christensen, 1981) to 19% (Coetzer and Tilbury, 1982;
Isbister et al., 2000) up to a maximum 40% (Wilkinson,
1994). In Brazil, an incidence of about 10–20 cases of
anaphylactic reactions for every 20,000 injections has been
estimated for the last ten years (Melgarejo, personal
communication). Even with these possible side effects,
there is good evidence that in cases of severe envenoming
the beneﬁts from the treatment with antivenom outweigh
the risks of adverse reactions (Warrell, 1996; Chen et al.,
2000).
Clinically, anaphylaxis is an exaggerated response of a
sensitized patient, someone with circulating IgE antibodies
that can react with the proteins administered in the anti-
venom, which causes the degranulation of mast cells and
basophiles. Degranulation leads to the release of histamine,
serotonin and other vasoactive substances. An anaphylactic
reaction can cause multiple signs and symptoms such as
itching, erythema, ﬂushing, urticaria, angioedema, nausea,
diarrhea, vomiting and edema of the glottis/larynx, bron-
chospasm, hypotension, shock and death. Anaphylactoid
reactions are clinically similar to anaphylactic reactions, but
are not mediated by IgE (Kay, 2001).
Antibodies are proteins produced by B-cells in response
to immunogenic substances. Although much is known
about the structure-function of this immunological class of
proteins, there is limited published evidence about the
precise localization of antigenic sites contained within the
antibodies themselves (Terness et al., 1995). This is in
contrast to their considerable biotechnological and immu-
notherapeutic importance since the administration of
horse immunoglobulin (hIg) preparations in humans
carries the inherent risk of inducing an allergic response in
a signiﬁcant number of people (Sutherland and Lovering,
1979; Ellis and Smith, 1988; Demoly et al., 2002; Williams
et al., 2007; Morais and Massaldi, 2009). To date, the
recognition of hIg by human antibodies and the speciﬁc
residues involved remain unknown.
Therefore, a detailed molecular characterization of the
epitopes in hIg that are bound by human antibodies would
greatly contribute to our understanding of the observed
adverse reactions. Here, the horse heavy chain of immu-
noglobulin G3 (hhcIgG3) was examined since it is themajor
hIg isotype implicated in the snake venom toxinsneutralization (Fernandes et al., 2000) and it is the second
most prominent antibody in horse serum (Sheoran et al.,
2000). In the present study, we have mapped within the
entire sequence of hhcIgG3 the epitopes bound by human
IgG and IgE along with the critical amino acids within the
epitope involved with interactions with human antibodies.
The identiﬁcation of the important amino acids suggests
different molecular mechanisms for the binding of IgG and
IgE to hhcIgG3.
Localizing antigenic determinants within the poly-
peptide chains of protein molecules is essential for subse-
quent investigations of structural and functional
characteristics. By identifying and quantifying components
in hIg that contribute to immunological discrimination
between self and non-self, antivenoms and antitoxins can
be improved by new production techniques engineered
speciﬁcally to minimize activation of a patient’s immune
response, but maintain efﬁcacy.
2. Material and methods
2.1. Reagents
Amino-PEG500-UC540 cellulose membranes were ob-
tained from Intavis AG Bioanalytical Instruments (Ger-
many). Amino acids for peptide synthesis were purchased
from Calbiochem–Novabiochem Corp. (Germany). Aceto-
nitrile, triﬂuoroacetic acid and other sequence reagents and
chemicals were obtained from Merck (Darmstadt, Ger-
many). Rabbit anti-human-IgG and goat anti-human IgE
immunoglobulin labeled with alkaline phosphatase were
purchased from Abcam plc (USA) and KPL (Kirkegaard &
Perri Laboratories, USA), respectively. The immunoperox-
idase assay kit for determining the level of IgE in human
samples was purchased from Immunology Consultants Lab
(Newberg, USA). Super Signal R West Pico and chemilu-
minescent substrate were acquired from Pierce Biotech-
nology (Rockford, IL, USA). Bovine serum albumin and
Tween 20 were obtained from Sigma–Aldrich.
2.2. Human sera
The pool of human serum that served as the IgG anti-
bodies source was collected from ﬁfteen healthy volunteers
who had been treated over a period of 4–12months with at
least one injection of antivenom produced in horses and
had no history of hypersensitivity. The source of IgE anti-
bodies was from three selected patients, who had been
victims of one or more snake bites and who had presented
with a severe anaphylactic reaction when treated with a
series of three injections of antivenom (polyvalent anti-
bothropic sera). The concentration of IgE was measured
as described below.
The allergic response was conﬁrmed by clinical history
and positive response to hIg, and characterized by
measuring speciﬁc IgE reactivity. A pool consisting of equal
volumes of sera from ﬁfteen health individuals who had
never received any therapeutically injection products pro-
duced in horses were used as a control. Informed consent
was obtained from all patients and volunteers. Our study
was approved by the Ethics Committee of the Santa Casa de
S.G. De-Simone et al. / Toxicon 78 (2014) 83–93 85Misericórdia do Rio de Janeiro (028/10) Hospital and by the
Fundação Oswaldo Cruz/IFF (0071/10).
2.3. Determination of IgG and IgE in human sera
The concentrations of human IgG and IgE were deter-
mined by enzyme-linked immunosorbent assay (ELISA) in
96-well microtiter plates (Nunc F Immunoplates I; Nunc,
Roskilde, Denmark). Brieﬂy, in this assay, the IgG or IgE
present in human sera samples reacted with anti-human
IgG and IgE antibodies, respectively, previously adsorbed
on the surface of a polystyrene microtitre wells. After
removal of unbound proteins by washing, a second set of
anti-human IgG or anti-human IgE antibodies conjugated
with horseradish peroxidase (HRP) were added. After
another washing step, the enzymes bound to the immu-
nosorbent were assayed by the addition of 3,30,5,50-tetra-
methylbenzidine (TMB). The quantity of bound enzymes
varied directly with the concentration of antibodies in the
sample; thus, the absorbance, at 450 nm, was a measure of
the concentration of IgG and IgE in the test sample. The
quantity of IgG and IgE in the test sample were interpolated
from a standard curve constructed with known standards
and corrected for sample dilution.
2.4. Bioinformatic analysis
DNA sequences derived from the horse (Equus caballus)
IgG3 heavy chain (GenBank: CAC86339.1) and the human
(Homo sapiens) IgG3 heavy chain constant regions (Gen-
Bank: CAA67886.1) were retrieved from the National Cen-
ter for Biotechnology Information database.
2.5. Synthesis of the cellulose-membrane-bound peptide
array
A library of peptides (Fig. 1C) was designed to represent
and cover the entire coding region (354 amino acids) of the
heavy chain horse IgG3 protein. Each peptide was 14 amino
acids in length and offset from its neighboring peptide by
ﬁve amino acids. Synthesis was automatically performed
onto Amino-PEG500 cellulose membranes according to
standard SPOT synthesis protocols (Frank, 1992) using an
Auto-Spot Robot ASP222 (Intavis, Koeln, Germany).
Coupling reactions were followed by acetylationwith acetic
anhydride (4% v/v) in N, N-dimethylformamide to block the
peptides during subsequent steps. After acetylation,
deprotection was performed to remove F-moc protective
groups by the addition of piperidine, which rendered the
nascent peptides reactive. The remaining amino acids were
added by this same process of coupling, blocking and
deprotection until the desired peptide was generated. After
the addition of the last amino acid in the peptide, amino
acid side chains were deprotected using a solution of
dichloromethane–triﬂuoroacetic acid–triisobutylsilane
(1:1:0.05, v/v/v) and washed with methanol. Membranes
containing the synthetic peptides were either probed
immediately or stored at 20 C until needed. Negative
controls [without peptide] and positive controls [IHLVN-
NESSEVIVHK (Clostridium tetani) precursor peptide] were
included in each assay.2.6. Screening of SPOT membranes
SPOT membranes were washed with 50 mM Tris Buff-
ered Saline (TBS; pH 7.0) and then blocked with TBS with
3% casein and 0.1% Tween 20 (TBS-CT) under agitation at
room temperature or overnight at 4 C. After extensive
washing with TBS with 0.1% Tween 20 (TBS-T), membranes
were incubated for 2 h with diluted human patient sera
(1:250 for IgG and 1:100 for IgE) in TBS-CTand thenwashed
again with TBS-T. Subsequently, membranes were incu-
bated with rabbit alkaline phosphatase labeled anti-human
IgG (diluted 1:5000) or goat alkaline phosphatase labeled
anti-human IgE (diluted 1:1000) prepared in TBS-CT for 1 h,
and thenwashed with TBS-T and CBS (50 mM citrate-buffer
saline). The chemiluminescent substrate (CDP Star Ready-
to-use Nitro-Block II, Applied Biosystems, U.S.A) was
added to detect positive reactions.
2.7. Scanning and measurement of spot signal intensities
Measurements of the spot signal intensities were ob-
tained as described previously (De-Simone et al., 2013b).
Brieﬂy, the chemiluminescent signals were measured and a
digital image ﬁle generated on a MF-ChemiBis 3.2 (DNR
Bio-Imaging Systems, Israel) with a resolution of 5 MP.
Signal intensities were quantiﬁed with TotalLab Software
(Nonlinear Dynamics, USA) using algorithms that
compared the intensity between background, spot area and
negative control to deﬁne the empirical probability that the
spot signal intensity was distinct from background signals.
The spot with the strongest signal on the membrane was
reported as having 100% intensity, and all other spots had
their intensity values expressed a relative percentage to
this intensity. Only spots with intensity values above 30%
were considered in the overlapping of reactive peptides.
2.8. Hydropathy
A hydropathy plot with a window size of 9 was used to
span the epitopes to deﬁne the hydrophobicity of the
hhcIgG3 over the length of the peptide sequence (Kyte and
Doolittle, 1982).
3. Results
3.1. Identiﬁcation of the immunodominant IgG and IgE
epitopes in hIgG3
Two pools of sera were generated to provide either
human IgG antibodies or human IgE against horse heavy
chain IgG3. The sera with human IgG were stimulated in
volunteers that were known not to be sensitive to treat-
ment (NST) by the injection of horse sera-based antivenom.
Sera containing human IgE was collected from volunteers
who had a known sensitivity (ST) to horse-based immu-
nological treatment. The concentration of IgG from the NST
group ranged from 9 to 15 mg/ml as measured by ELISA
(data not shown) and IgE in the serum from the ST group
was 9–15 mg/ml (group NST) before pooling.
The regions of the primary sequence of hIgG recognized
by human IgG and IgE sera were determined using three
Fig. 1. Binding of human IgG to a cellulose-bound peptide library representing hhcIgG3. An overlapping array of 69 peptides shifted 5 amino acids from each
other were probed with a 1:250 dilution of a pool of human sera detected by alkaline phosphatase labeled rabbit anti-human IgG and chemiluminescence. (A)
Relative signal intensity of bound human IgG to each position from the membrane. 100% was deﬁned by the positive control and 0% by the negative control. (B)
Image of the membrane showing the reactivity at each spot and the positions used to make the measurements presented in panel A. (C) Lists the individual
peptides spanning the hhcIgG3 (GenBank ac number: AB100095) and constitute the library with their positions on the membrane. Spots C22 & C23 correspond to
the positive peptide controls and the negative control at C24 were a single glycine spotted on the membrane. Only spots with intensities 30% were considered in
the overlapping.
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each. The peptides were directly synthesized simulta-
neously onto cellulose membranes by standard SPOT pro-
tocols. Each synthesized peptide consisted of 14 amino
acids and was offset by ﬁve amino acids from the previous
peptide. Prior to exposing the peptide libraries to test pools
of human IgG (NST) or IgE (ST), the membranes were
incubated with healthy human control sera (group HCS) to
evaluate non-speciﬁc antibody binding. No appreciable
signal was detected (<30% cutoff; not shown).
The data for the recognition pattern of human IgG
binding to the peptide library spanning the hhcIgG3 coding
sequence is shown in Fig. 1. In panel A, normalized
measured intensities from chemiluminenscence are pre-
sented with 100% deﬁned as described in the Materials and
Methods. An image from a representative membrane pre-
senting the peptide library is shown in Fig. 1 panel B. A list
of the peptides and their coordinates on the membrane are
listed in Fig. 1 panel C. The arrangement of the signals is
observed in groupings with a single peptide normally
presenting a higher signal surrounded or followed by
peptides with decreasing intensities. This pattern of vary-
ing intensities suggests that certain amino acids within an
epitope are of greater importance for antibody binding
than others and if they are retained in the peptide there are
still interactions between antigen and antibody.
A different pattern was observed with pooled sera of
group ST containing human IgE. While human IgGFig. 2. Analysis of human IgE reactivity to a cellulose-bound synthetic peptide libr
amino acid sequence of hhcIgG3 was probed with a 1:100 dilution of human sera f
rabbit anti-human IgE labeled with alkaline phosphatase and chemiluminescence
Relative signal intensity of bound human IgE antibodies with 100% deﬁned by the p
positions is the same as in Fig. 1C. Only spots with intensities 30% were considerrecognized multiple epitopes in hhcIgG3, the sensitive
human sera (group ST) that were rich in IgE recognized a
single epitope (Fig. 2). This epitope was identiﬁed by the
strong signal intensity presented in the spot B13 (Fig. 2B).
Other spots with small intensities are identiﬁable from the
presentation of the ﬁgure (A9, A18, B24), but their in-
tensities were below 30%, which is below the cutoff to be
considered an epitope.
From the SPOT membrane analysis, seven prominent
IgG epitope regions were identiﬁed and are listed in Table 1.
The human IgG-binding regions were comprised of the
amino acid residues P6-S14, L46-P54, C131-L140, C165-
D174, D185-V189, W286-Y298 and T321-T329 of the
hhcIgG3 sequence and were designated as epitopes hIgG3-
1 through -7, respectively. The epitope recognized by
human IgE was represented by the amino acids D177-V189
and encompassed the epitope hIgG3-5 that was recognized
by human IgG.
The epitopes are located in various regions of the heavy
chain. In comparison to the sequence of human IgG3, the
position of epitopes hIgG3-1 and -2 epitopes corresponded
to the CH2 domain in the F(ab’)2 of human IgG (Fig. 3). The
hIgG3-3 epitope was located in the Fc hinge region, while
the epitopes hIgG3-4 through -7 were situated in the CH3
domain of the Fc region. The epitope bound by human IgE
was the same as hIgG3-5 and therefore it was also located
in the CH3 domain of the Fc region. The comparison also
showed that each of the epitopes discovered in the horseary representing hhcIgG3. A membrane spotted with peptides that span the
rom volunteers sensitized to horse sera. Bound antibodies were detected by
. Image of the membrane showing the measured chemiluminescent signal.
ositive controls and 0% by the negative control. The list of peptides and their
ed in the overlapping.
Table 1
Deﬁned epitopes in hhcIgG3 recognized by human IgG and IgE antibodies as deduced from Spot synthesis analysis and hydropathy plots. The sequence of
each epitope is a result of overlapping of the set of positive spots.
Epitope IgG-Sequence IgE-Sequence Globulin-Domain
hIgG3-1 6PKVFPLAPS14 Variable
hIgG3-2 46LTSGVRTFP54 Variable
hIgG3-3 131CPKCPAPELL140 Hinge
hIgG3-4 165CLVVDVSHD174 CH2
hIgG3-5 185DGTEV189 177DVLFTWYVDGTEV189 CH3
hIgG3-6 286WQSNEHPEPEGKY298 CH3
hIgG3-7 321TDRWQQGTT329 CH3
S.G. De-Simone et al. / Toxicon 78 (2014) 83–9388heavy chain have numerous differences in the corre-
sponding human sequence (Fig. 3).3.2. Analysis of individual sera
To investigate possible differences in the pattern of
recognition for epitopes between donor sera, the serum
from two individual patients from group 2 (anaphylactic
donors) were analyzed for IgG antibodies and two sera
from patients in group 1 (non anaphylactic donors) were
evaluated for IgE bind epitopes. The Spot synthesis results
showed that both patients in group 2 had IgG antibodies in
their serum that recognized the same pattern of epitopes,
but with different intensities, compared to the IgG’s in the
pool of sera from group 1, while the sera from the patients
of group 1 did not recognized the major epitope recognized
by the IgE present in the pool of sera from group 2 (data not
shown). This result demonstrated that if there was vari-
ability in epitope recognition for each individual within the
groups of donors. but the variability was not qualitative andFig. 3. Localization of the antigenic determinants in hhcIgG3 recognized by human
human IgG are displayed in pink and binding by human IgE is shown in green. Da
sequence alignment. The numbers on the left and right sides indicate amino acid po
within epitopes are highlighted in yellow. Overall, the identity between hhcIgG3 (Ge
interpretation of the references to colour in this ﬁgure legend, the reader is referredid not inﬂuence the discovery of the epitopes deﬁned by
the pooled sera.3.3. Critical residues of the linear epitope for human IgG
binding
The overlap of residues in the peptides located in the
positive spots suggested the underlined peptide amino acid
sequence (176SDVLFTWYVDGTEV189) as the putative
epitope for human IgG. A set of eight peptides (P13–P20)
were synthesized to contain truncated and/or substituted
amino acids for reﬁning the amino acid sequence required
for human IgG binding. The amino acids Lys190 and Thr191
did not contribute to binding as shown by the 100% reac-
tivity for the two peptides P13 (181TWYVDGTEVKTA192)
and P14 (181TWYVDGTEVAAA192), in which those resi-
dues were replaced by alanine (Fig. 4B). Themutation of the
N-terminal block sequence 181TWYV184 also did not cause
any change in the pattern of reactivity with human IgG
antibodies as observed with P15. However, the suppressionantibodies in comparison to the sequence of human IgG3. Epitopes bound by
shes represent the absence of comparative amino acids and provide better
sitions. Speciﬁc differences within the horse and human sequences contained
nBank: CAC86339.1) and human IgG3 (GenBank: CAA67886.1) was 66%. (For
d to the web version of this article.)
Fig. 4. Analysis of critical amino acids in hIgG3 for epitope recognition by human antibodies. Two mini-peptide arrays were prepared by Spot technology that
varied a sequence by substituting adjacent groups of amino acids with alanine (A) or glycine (G). The arrays were probed with pooled human sera followed by
anti-human second secondaries and chemiluminescence. The intensities for each peptide are plotted based on calculations relative to 100% for the positive
controls and 0% for the negative control. The peptide sequences are listed above the plots. (A) The epitope TWYBDGTEVKTA and variations recognition by human
IgG antibodies. (B) The epitope DSSDVLFTWYVDGTEV and variations binding by human IgE antibodies. The data are the average of three (4–7%) independent
experiments. SI, signal intensity.
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greater decrease, by a factor of 2, was observed for P17
when Asp (D185) was changed to alanine, which supports
its important role in recognition by human IgG. The critical
amino acids were reﬁned by the peptides P18 and P19. The
substitution of the N-terminal Gly186 residue for the hy-
drophobic residue Val186 in P18 affected the binding of
human IgG drastically and led to a complete loss of the IgG
binding. The absence of Thr187 and Glu188 in P19 also
completely abolished interaction with human IgG. These
ﬁndings indicated that the ﬁve-residue peptide containing
the sequence 185DGTEV189 was the minimal effective
sequence peptide for 100% human IgG binding and that the
three residues 186GTE188 were absolutely critical for IgG-
binding.3.4. Critical residues of the linear epitope for human IgE
binding
For further investigation, twelve peptides (P1–12) were
designed and synthesized with mutations on the right and
left sides of the central critical building block of the puta-
tive IgE-binding. This region was chosen because of their
exposure to the solvent and because together they consti-
tute one of the most accessible surface areas (Fig. 5) of the
molecule to the immune system. To determine the inﬂu-
ence of the adjacent amino acids and the crucial residues
for conversion to binding by human IgE, a longer sequence
(174DSSDVLFTWYVDGTEV189) was analyzed than for
human IgG. Fig. 4B shows the reactive intensity of themodiﬁed peptides after being probed with the IgE hyper-
immune patients’ sera.
The introduction of the tripeptide DSS and KTA in the
N- and C-terminal positions, respectively, of the base
epitope peptide (177DVLFTWYVDGTEV189) neither
increased nor decreased the IgE binding (peptides P1 and
P3). Conversely, the hydrophobic sequence 182TWYVD186
proved to be important since its replacement with AAAAA
had a negative effect on the IgE binding (peptide P5).
Likewise, the result for peptide P6 showed that the
replacement of D177, L179 and T181 with Ala signiﬁcantly
diminished its IgE-binding capacity, while the substitution
of TEV had little effect on the binding (peptide P9). The
exclusion of T181 from the block 181TWYVDGTEV189 also
did not decrease the IgE bind (peptides P7 and P8), but the
subtraction of the block 180 FTWYVDGTEV189 drastically
affected recognition of peptide P12 by human IgE. The
results suggest that the residues 177-DVLF-180 and the
hydrophobic sequence 181TWYV184 (in peptide P11)
contained within the linear epitope are critical for human
IgE binding to hhcIgG3.3.5. Accessibility of the antigenic determinants
A hydropathy plot representing the location of the seven
immunodominants epitopes determined with a window of
9 amino acids is shown in Fig. 5. This plot shows that the
immunogenic peptide sequences that are more exposed to
the molecular surface of the hIg are: hIgG3-5
(185DGTEV189) and hIgG3-6 (286WQSNEHPEPEGKY298).
Fig. 5. Hydropathy proﬁle of hhcIgG (window size 9) representing the location of the different immunodominant epitopes. Solid lines indicate the regions of the
epitope location corresponding to the positions of the amino acids. Numbers 1–7 refer to epitopes P6-S14, L46-P54, C131-L140, C165-D174, D185-V189, W286-
Y298 and T321-T329, respectively, as listed in Table 1. D177-V189 (DVLFTWYVDGTEV) corresponds to the epitope IgE.
S.G. De-Simone et al. / Toxicon 78 (2014) 83–9390These segments were determined to be themost reactive to
binding by human antibodies as seen in Figs. 1 and 2.
3.6. Ethics statement
We conﬁrm that any aspect of the work covered in this
manuscript that has involved either experimental animals
or human patients has been conducted with the ethical
approval of all relevant bodies and that such approvals are
acknowledged within the manuscript.
4. Discussion
Snake bite envenoming is a major health care concern
throughout the world (Gutiérrez et al., 2006). An effective
medical intervention that provides passive immunity is
antivenom prepared in horses. However, hypersensitivity
to horse-based sera therapies is a potentially life threat-
ening reaction in patients. Although the worldwide inci-
dence of mortality is not high, it is an important health
issue since it is a constant possibility. Various studies have
concentrated on the potential of equine immunobiologicals
to provoke reactions in patients of either an early type
(anaphylactoid) (Moran et al., 1998; Chen et al., 2000) or of
late onset (serum sickness) (León et al., 2001). The major
allergenic molecule involved has been identiﬁed as whole
immunoglobulins present in the immunological prepara-
tions of horse sera (León et al., 2008). The onset of allergic
reactions can be minimized by premedication of patientsbefore administering antivenom (Cupo et al., 1991;
Gawarammana et al., 2004; Williams et al., 2007; de Silva
et al., 2011). Yet, to advance antivenom therapies through
improved production methods, it is important to under-
stand the molecular events related to adverse reactions.
Our approach was to identify the epitopes in a horse
immunoglobulin, the active constituent of antivenom,
recognized by human IgG and IgE because the generation of
human IgG relates to serum sickness and IgE plays a critical
role in the etiology of allergen-speciﬁc responses.
Here, we identiﬁed the amino acid sequences of the
linear epitopes that constitute the antigenic sites in the
horse IgG3 protein heavy chain, the second most prevalent
horse sera Ig (Sheoran et al., 2000) and the ﬁrst involved in
snake bites toxin recognition (Fernandes et al., 2000). The
epitopes were located and mapped using the Spot-
synthesis technique. Since the minimum antigenic site
has been demonstrated to consist of ﬁve-residues, which is
sufﬁcient to bind a detectable quantity of recognizing an-
tibodies (De-Simone et al., 2013a), the panel of peptides
representing hhcIgG3 were offset by ﬁve amino acids.
Furthermore, this avoided scission of antigenic sites to
provide full coverage of the coding regions for all possible
epitope regions.
This library of peptides was probed with sera pooled
from three distinct groups of people. Group 1 (n ¼ 15) sera
provided primarily human IgG and was collected from
patients who had received multiple doses of horse immu-
nological preparations without presenting any indications
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clinically recognized as being hypersensitive to horse
serum and provided human IgE against hhcIgG3. The third
group (n ¼ 15) served as a control and was obtained from
individuals who had never been exposed to horse sera
preparations. The concentration of the two distinct classes
of immunoglobulins in the human sera ranged from 9 to
15mg/ml for IgG and 320–410 ng/ml for IgE, which equates
to 10,000 to 1 million fold bias towards IgG than IgE (Ledin
et al., 2008). To account for this bias, the optimal dilution of
each pool was empirically determined for detection of
positive peptides spots. For IgG, the best detection occurred
with a dilution of 1:250 and 1:100 for IgE detection. The
difference between bias and the detection dilution suggests
that human IgE had a greater afﬁnity for hhcIgG3 than
human IgG.
The control group 3 was an important component of the
experimental design because it was reported that healthy
people maywell present antibodies that cross-react against
the hinge region of hIg (Terness et al., 1995). In our assays
using the sera of Group 3, no cross reactivity was detected
(data not shown). Conversely, the Group 1 sera readily
identiﬁed seven major IgG epitopes while for group 2 there
was only a single major IgE epitope (Table 1). Two of the
human IgG antigenic determinants were located in the
variable region of the F(ab’)2, one epitope in the hinge re-
gion, four to the Fc region, one in the CH2 domain and three
in the CH3 domain (Table 1). These ﬁnding conﬁrmed
previous reports suggesting that exaggerated human
exposure to horse immunological preparations generates a
strong IgG-based response (Rojnuckarin et al., 1998; Sevcik
et al., 2008). Furthermore, the results strongly suggest that
the presence of antibodies against the Fc regionswas due to
the presence of intact hhcIgG3 in these preparations since
only two correlated with the F(ab’)2 that are isolated from
the pepsin digest of horse immunoglobulin during
preparation.
An important aspect of site recognition is regulated by
the MHC of the host with the response to each site being
under separate genetic control (Okuda et al., 1978, 1979).
This separation allows the immunodominance of anti-
bodies directed against a given site to vary between host
species and even between individuals within a given spe-
cies such that frame shifts in the amino acid sequence of
epitopes recognized by antibodies can be observed (Atassi,
1982). A comparison between the sites recognized in
hhcIgG3 by human and rabbit antibodies are consistent
withMHC of the host being amajor cause for frame shifts in
the epitope sequences and the level of antibody response.
Previous results using the same strategy with rabbit hy-
perimmune sera raised against hhcIgG3 identiﬁed 11
immunodominant regions distributed throughout the
antibody heavy chain (De-Simone et al., 2013b). The re-
gions deﬁned as 3 and 5 in the human response dis-
played a 1–2 residue shift in amino acids compared to
rabbit, while regions 1 and 2 exhibited left and right
shifts of 1 and 5 residues, respectively. Six other antigenic
regions recognized by the immunized rabbit sera were not
reactive with human IgG (De-Simone et al., 2013b). This
result stresses the necessity to conﬁrm antibody responses
observed in other systems directly with those in humans.Sera was only available from three patients hypersen-
sitive to horse sera for use in identifying the epitopes
recognized by human IgE since such patients are difﬁcult to
recruit. Notwithstanding, a single immunodominant anti-
genic determinant was identiﬁed that contained thirteen
amino acids (D177-V189; Fig. 2 and Table 1). This antigenic
determinant was located in the CH3 region as expected for a
reaction against contaminating whole hhcIgG3 molecules.
Interestingly, it contained an overlapping sequence of 5
residues 185–189 (DGTEV) that was recognized by human
IgG. This epitope forms a loop in the residues
177DVLFTWYVDGTEV189 and its high signal intensity
during detection suggested that the loopwasmaintained in
the peptide (spot B13, Fig. 2).
Since amino acid characteristics in an epitope
contribute to antigenicity, the hydrophobicity, polarity and
charge of each were determined (Fig. 5). The relative hy-
drophobicity of the epitope, as determined by the Kyte and
Doolittle method, identiﬁed the IgE epitope as a relatively
hydrophobic region of the protein (Fig. 5). Of the 14 amino
acids, hydrophobic residues were the most frequent (6/14),
followed by polar residues (4/14) and charged residues (4/
14). To determine the critical amino acids, a panel of pep-
tides with various mutations were synthesized. A major
change in the IgE reactivity was observed with the peptides
containing the hydrophobic sequence (181TWYV184)
replaced with truncated peptides or substituted amino
acids. The sequence 177-DVLF-180 was also shown to be
necessary for the binding to IgE. This was suggested by the
results whereby the reactivity to P5–P8 and P11 were
markedly reduced (15–50% reactivity) by substitution with
Ala. With regard to the remaining residues between posi-
tions 185–189, all showed rather weak but important
reactivity (w40% reactivity) in Ala-scanning experiments
(P4 and P11), indicating that 185-DGTEV-189 are associated
with the reactivity of P4 and P11 with IgE. Taken together,
thirteen residues (177DVLFTWYVDGTEV189) were
concluded to be critical for the IgE-binding.
It is interesting to note that as many as four of the
thirteen critical residues have an electrically charged side
chain, being likely to form salt bridges with IgE. Indeed, salt
bridges are known to signiﬁcantly contribute to speciﬁcity.
Differing from the situation for human IgG binding to the
same epitope region that was restricted to ﬁve amino acids
(185DGTEV189) with three critical residues (186GTE188),
the determined critical residues in the IgE epitope were
mostly hydrophobic. This result led us to conclude that
hydrophobic interactions, which are generally known to
have essential roles in stabilizing protein–protein in-
teractions (Kobayashi et al., 2010), are directly involved in
the binding of hIg by human IgE considering that the side
chains of Try (W), Tyr (Y), Phe (F) and Val (V) participate in
a hydrophobic cluster made from hydrophobic side chains
of adjacent residues (Val-178, Phe-180, W182, Tyr-183 and
V-184), which would strengthen the hydrophobic interac-
tion with IgE.
Considering the high level of similarity between the
sequence of human and horse IgG3, an alignment was
performed to understand the absence of self-recognition.
The alignment shows that the main difference between
the human and the horse IgG3 proteins structure are in the
S.G. De-Simone et al. / Toxicon 78 (2014) 83–9392residues V189-H190 and for IgE either D177, L179 or T181
(Fig. 3). These amino acids correspond to the critical resi-
dues for human IgG and IgE binding to hhcIgG3.
5. Conclusions
In conclusion, we have demonstrated that individuals
with and without hypersensitivity to antivenom produce
antibodies to sequential epitopes of hhcIgG3, although the
signal strength and speciﬁcity appear to be distinct in the
both groups of patients. The major IgE- epitope of hhcIgG3
is included in the CH3 domain of the Fc region (Fig. 2; spot
B13, region 116–130) and consisted of nine amino acid
residues. The principal IgG-binding epitope was restricted
to ﬁve critical amino acids, which are part of the IgE
epitope. Each class of human immunoglobulin appeared to
bind through different mechanisms. The determined crit-
ical residues of 185DGTEV189 for IgG and 181TWYVDG-
TEV189 for IgE suggests that binding occurs through
electrostatic and hydrophobic interactions, respectively.
This is the ﬁrst study to describe the speciﬁc amino acid
sequences involved in the immune recognition of horse
antivenom. Overall, our data should advance the develop-
ment of processes to produce hypoallergenic recombinant
human immunoglobulin mutants that are practical anti-
gens for allergen-speciﬁc immunotherapy and for the
diagnosis of allergies to hIg.
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